Klebsiella Pneumonia
5
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
Clinical Outcomes in Patients With Infection by Resistant Microorganism
Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia
Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms